arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CYTOKINETICS INC

CYTK
$55.89 ▼ -9.07 (-13.96%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
78 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Bullish
auto_awesome

Analytical Summary

CYTOKINETICS INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $7.4M
Dividend Yield —
Revenue Growth -57.1% ↘
Op. Margin None
ROIC -189.4% ↘
FCF / Share None
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -1.43
info Valuation on last close. End-of-day price, Nov 5, 2026.

78-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$28.62M
↓ -57.1% —
Net Income Profit after all expenses
$-206.03M
↓ -27.7% —
Operating Margin Operating profit as % of sales
-167.0%
↓ -1266.4% —
Long-Term Debt Long-term obligations
$248.20M
— +0.4% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
99
Financial Health ↓
64
Cash Quality ↓
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 28 years · 78 quarters